Cancer Immunity (19 October 2007) Vol. 7, p. 16

NY-ESO-1 is a cancer-testis antigen and an attractive target for immunotherapy in patients with different malignancies. Here we report the results of a phase I clinical study of intensive course NY-ESO-1 peptide vaccination, evaluating the safety, immunogenicity and clinical response in HLA-A2 positive patients with NY-ESO-1 expressing cancers. Of 20 patients enrolled in the trial, 14 completed at least 2 cycles of immunization and were evaluable for clinical and immunological response. Five of these evaluable patients were treated in cohort 1 (baseline seropositive) and 9 patients were treated in cohort 2 (baseline seronegative). During vaccination, NY-ESO-1-specific CD8+ T-cells were induced in 3 of 9 baseline seronegative patients. In patients with pre-existing antigen-specific CD8+ T-cells, their number increased or remained stable. In contrast to previous immunization protocols with less intensive immunization schedules, we observed a rapid induction of high magnitude NY-ESO-1 peptide-specific T-cell responses detectable already on day 15-22 of immunization. A specific immune response of high magnitude and early onset may be more effective in eliminating minimal residual disease in adjuvant treatment situations and in preventing tumor progression due to immune escape mechanisms.

[1]  J. Karbach,et al.  Tumor‐reactive CD8+ T‐cell clones in patients after NY‐ESO‐1 peptide vaccination , 2007, International journal of cancer.

[2]  D. Jäger,et al.  Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients , 2006, Proceedings of the National Academy of Sciences.

[3]  L. Old,et al.  Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients , 2006, Journal of immunotherapy.

[4]  L. Old,et al.  In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. , 2006, The Journal of clinical investigation.

[5]  A. La Cava,et al.  CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. , 2006, Trends in immunology.

[6]  Bent K Jakobsen,et al.  Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors , 2006, The Journal of Immunology.

[7]  K. Odunsi,et al.  Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination1 , 2006, The Journal of Immunology.

[8]  D. Purcell,et al.  Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. , 2006, Vaccine.

[9]  D. Speiser,et al.  Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. , 2006, Cancer research.

[10]  L. Old,et al.  A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. , 2006, Clinical immunology.

[11]  E. Jaffee,et al.  Immunotherapy for pancreatic cancer — science driving clinical progress , 2005, Nature Reviews Cancer.

[12]  E. Jaffee,et al.  Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response , 2005, The Journal of experimental medicine.

[13]  R. Hruban,et al.  Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.

[14]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Monden,et al.  NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors , 2004, Cancer Research.

[16]  Yao-Tseng Chen,et al.  Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. , 2004, Cancer immunity.

[17]  P. Coulie,et al.  Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide 1 , 2003, The Journal of Immunology.

[18]  K. Itoh,et al.  Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination , 2003, The Prostate.

[19]  Yao-Tseng Chen,et al.  NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. , 2003, Cancer research.

[20]  Yao-Tseng Chen,et al.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[22]  Danila Valmori,et al.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. , 2002, The Journal of clinical investigation.

[23]  P. Coulie,et al.  Cytolytic T‐cell responses of cancer patients vaccinated with a MAGE antigen , 2002 .

[24]  Yao-Tseng Chen,et al.  CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Scott E Kern,et al.  Focus on pancreas cancer. , 2002, Cancer cell.

[26]  M. Lotze,et al.  Complementary Dendritic Cell–activating Function of CD8+ and CD4+ T Cells , 2002, The Journal of experimental medicine.

[27]  V. Engelhard,et al.  Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  V. Engelhard,et al.  Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients , 2001, International journal of cancer.

[29]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Jäger,et al.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  V. Cerundolo,et al.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Speiser,et al.  Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. , 2000, Cancer research.

[33]  V. Cerundolo,et al.  Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1 , 2000, The Journal of Immunology.

[34]  P. Kantoff,et al.  A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  D. Jäger,et al.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[37]  D. Jäger,et al.  Humoral immune responses of cancer patients against “Cancer‐Testis” antigen NY‐ESO‐1: Correlation with clinical events , 1999 .

[38]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[39]  H. Pircher,et al.  On the role of antigen in maintaining cytotoxic T-cell memory. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  F. Oesch,et al.  Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.

[41]  J. Sprent,et al.  Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro , 1996, The Journal of experimental medicine.